^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation....Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.
    Secondary therapy:
    dexamethasone; pegylated liposomal doxorubicin
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    VELCADE is a proteasome inhibitor indicated for...treatment of adult patients with multiple myeloma
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN multiple myeloma panel members have included the bortezomib and dexamethasone regimen as an option for patients with relapsed/refractory myeloma (category 1). Primary therapy for transplant canditates:…Useful In Certain Circumstances:...Bortezomib /doxorubicin/dexamethasone
    Secondary therapy:
    doxorubicin hydrochloride + dexamethasone; dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Recommendations:...bortezomib may be considered for patients with high-risk disease [II, B].
    DOI:
    10.1016/j.annonc.2020.11.014
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Multiple Myeloma: Maintenance therapy…Other Recommended Regimens…Bortezomib
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lancet
    Title:

    Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

    Excerpt:
    Median progression-free survival was significantly improved in the VRd group (43 months vs 30 months in the Rd group…In patients with newly diagnosed myeloma, the addition of bortezomib to lenalidomide and dexamethasone resulted in significantly improved progression-free and overall survival and had an acceptable risk-benefit profile.
    Secondary therapy:
    lenalidomide + dexamethasone
    DOI:
    10.1016/S0140-6736(16)31594-X
    Trial ID:
    SWOG S0777